Skip to main content
Fig. 5 | BMC Infectious Diseases

Fig. 5

From: Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis

Fig. 5

The results of trial sequential analysis under two posaconazole TDM targets. a Trial sequential analysis in 20 trials for posaconazole concentration target of 0.5 mg/L. The required information size (RIS, i.e., number of participates) was calculated as 455. The Z curve crossed the conventional boundary of benefit and the vertical line of RIS. b Trial sequential analysis in 15 trials for posaconazole concentration target of 0.7 mg/L. The RIS was calculated as 693. The Z curve crossed the futility boundary and the vertical line of RIS

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us